EFFECTS OF SECOBARBITAL AND D-AMPHETAMINE ON TRACKING PERFORMANCE DURING ANGULAR ACCELERATION

David J. Schroeder, Ph.D.* William E. Collins, Ph.D.* Gary W. Elam, M.D.**

*FAA Civil Aeromedical Institute P.O. Box 25082 Oklahoma City, Oklahoma 73125

**Department of Otorhinolaryngology University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma 73104



December 1973

Availability is unlimited. Document may be released to the National Technical Information Service, Springfield, Virginia 22151, for sale to the public.

Prepared for DEPARTMENT OF TRANSPORTATION FEDERAL AVIATION ADMINISTRATION Office of Aviation Medicine Washington, D.C. 20591

TECHNICAL REPORT STANDARD TITLE PAGE

PAA-AM-73-17 .	1. Report No.	2. Government Acce	ssion No. 3.	Recipient's Catalog I	No.	
PAA-AM-73-17 1 3. Report Date EFFECTS OF SECOBARS TAL AND D-AMPHETAMINE ON TRACKING PERFORMANCE DURING ANGULAR ACCELERATION 5. Report Date TRACKING PERFORMANCE DURING ANGULAR ACCELERATION 6. Performing Organization Report No. and Gary W. Elam, M.D. 8. Performing Organization Report No. 7. Authorid 10. Work Unit No. 7. Performing Organization Remot Address 10. Work Unit No. 7. Authorid 10. Work Unit No. 7. Performing Organization Remot Address 10. Work Unit No. 7. Spensoring Agency Meme and Address 10. Work Unit No. 7. Spensoring Agency Meme and Address 0AM Report 7. Software Network State 0AM Report 7. Supportentioner Network State 0AM-D-74-PSY-27. 7. Authorid 1. Supportentioner Network State 7. Supportentioner Network State 0AM-D-74-PSY-27. 7. Authorid 1. Contract of Grant Not. 7. Supportentioner Network State 0AM-D-74-PSY-27. 7. A						
1. The and submits 10. Contrast 1973 EFFECTS OF SECOBARBITAL AND D-AMPHETAMINE ON TRACKING PERFORMANCE DURING ANGULAR ACCELERATION December 1973 7. Authorid) 5. Performing Organization Reserver Acceleration 6. Performing Organization Reserver No. 10. and Gary W. Elam, M.D. 10. Work Unit No. 6. Performing Organization Reserver No. 9. Performing Organization Name and Address 10. Work Unit No. 9. Performing Organization Name and Address 10. Work Unit No. 9. Performing Organization Name and Address 10. Work Unit No. 9. Performing Organization Name and Address 11. Connect or Grant No. 11. Sponsoring Agency Neme and Address 11. Connect or Grant No. 12. Sponsoring Agency Neme and Address 11. Connect or Grant No. 13. Supplementary Notes 11. Sponsoring Agency Cade 14. Sponsoring Agency Neme and Address 0. Address 15. Supplementary Notes 11. Sponsoring Agency Cade 16. Abstret 11. Sponsoring Agency Cade 17. Strapplementary Notes 11. Sponsoring Agency Cade 18. Supplementary Notes 11. Contract or Grant No. 19. Secondary agency Neme and Address 0. Address This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27.	FAA-AM-73-17		5	Penert Date		
EFFECTS OF SECORARD FLAD ARD D-APFELTABLIKE OK Image: Constraint of the second sec	4. Title and Subtitle	D D AMDITUTE ANT	J	December 1973	3	
7. Author(d) David J. Schroeder, Ph.D., William E. Collins, Ph.D., and Gary W. Elam, M.D. 8. Performing Organisation Ream of Address 7. Author(d) B. Performing Organisation Ream of Address 10. Work Unit No. 7. Author(d) B. Performing Organisation Ream of Address 10. Work Unit No. 7. Author(d) B. Performing Organisation Ream of Address 10. Work Unit No. 9. Performing Organisation Ream of Address 10. Work Unit No. 9. Okanowa City, Oklahoma 73125 11. Contract or Grant No. 12. Spensoring Agency News and Address 0AM Report Pederal Aviation Administration 0AM Report 800 Independence Avenue, S. W. 14. Spensoring Agency Code Washingtorn, D. C. 20591 15. Supplementary Netse This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet Thitry young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following groups: placebo vere administered in capsules in a double-blind procedure following groups in both static (stationary) and dynamic (angular acceleration, secobarbital subjects made significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. Newver, during angular acceleration, secobarbital subjects made significantl	EFFECTS OF SECOBARBITAL AN	D D-AMPHETAMI	NE ON	Performing Organizati	ion Code	
7. Auhofd) Bavid J. Schroeder, Ph.D., William E. Collins, Ph.D., and Gary W. Elam, M.D. 8. Performing Organization Resent Me. 9. Performing Organization Neams and Address 10. Work Unit No. 7. A Civil A erromedical Institute 11. Contract or Grant No. 9. Device of Aviation Medical Institute 11. Contract or Grant No. 12. Spansoring Agency Neams and Address 0AM Report 13. Type of Report and Period Covered 0AM Report 14. Spansoring Agency Neams and Address 0AM Report 15. Suplementary Notes 14. Spansoring Agency Code 16. Abstract 14. Spansoring Agency Code 17. Type of Report and Period Covered 0AM Report 16. Abstract 14. Spansoring Agency Code 17. Supplementary Notes 14. Spansoring Agency Code 18. Supplementary Notes 14. Spansoring Agency Code 19. starting the period Covered 0AM Report 10. Abstract 11. Contract or Grant No. 11. Supplementary Notes 11. Contract or Grant No. 12. Spansoring Agency Code 14. Spansoring Agency Code 13. Supplementary Notes 11. Contract or Grant No. 14. Spansoring Agency Code 11. Contract or Grant No. 15. Supplementane Notes	IRACKING PERFORMANCE DURIN	G ANGULAR ACC	ELERATION	erionning organizar		
David J. Schroeder, Ph.D., William E. Collins, Ph.D., and Gary W. Elam, M.D. Image: Scheme Schem	7. Author(s)	and the second	8. 1	Performing Organizati	ion Report No.	
9. Performing Organization Name and Address 10. Work Unit No. 9. O. Box 25082 11. Contract or Grant No. 12. Sponsoring Agency Name and Address 11. Contract or Grant No. 13. System of Aviation Medicine 11. Contract or Grant No. Pederal Aviation Administration 0AM Report 800 Independence Avenue, S. W. 14. Sponsoring Agency Code Washington, D. C. 20591 14. Sponsoring Agency Code 15. Supplementary Netwar 14. Sponsoring Agency Code This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following percentice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly more vestibular mystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produ	David J. Schroeder, Ph.D., and Gary W. Elam, M.D.	William E. C	ollins, Ph.D.,			
PA CLV11 Aeromedical Institute P. O. Box 25082 Oklahoma City, Oklahoma 73125 11. Contract or Grant No. 12. Sponsoring Agency Name and Addres: Office of Aviation Administration 800 Independence Avenue, S. W. Washington, D. C. 20591 15. Supplementery Notes This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet This research was conducted under Tasks of alconol file following research and excellention and excellention of the following research and excellention following research and	9. Performing Organization Name and Addres	15	10.	Work Unit No.		
1. O. DA 1302 In Type of Report and Period Covered 0klahome City, Oklahoma 73125 In Type of Report and Period Covered 12. Sponsoring Agency Name and Addres: Office of Avlation Medicine Pederal Aviation Addministration BOM Report 800 Independence Avenue, S. W. In Supersentation 800 Independence Avenue, S. W. In Supersentative Network This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-bilind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more vestibular nystagmus than bot the control and the d-amphetamine groups for all post-drug session in the detervionments, but may produce marked performance in static environments, but may produce marked performance in a tracking performance in not stroking performance in a tracking performance in thease wi	P O Boy 25082	ltute	11.	Contract or Grant No	0.	
12. Spensoring Agency Nems and Address 13. Type of Report and Period Covered 12. Spensoring Agency Nems and Address OAM Report 13. Type of Report and Period Covered OAM Report 14. Spensoring Agency Nems and Address OAM Report 15. Supplementery Notes 14. Spensoring Agency Code 15. Supplementery Notes 14. Spensoring Agency Code 16. Abstract Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Still-eWerner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more vestibular mystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appea	Oklahoma City Oklahoma 73	125				
12. Sponsoring Agency Name and Address OAM Report Office of Aviation Medicine OAM Report Federal Aviation Administration 800 Independence Avenue, S. W. 14. Sponsoring Agency Code Washington, D. C. 20591 15. Supplementary Notes 14. Sponsoring Agency Code This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstract Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular site environments or be a vestibular nystagmus by visual fixation is impaired. 17. Key Words 16. Distribution Statem	oklanona city, oklanona 75	125	13.	13. Type of Report and Period Covered		
Office of Aviation Medicine OAM Report Federal Aviation Administration OAM Report 800 Independence Avenue, S. W. Mashington, D. C. 20591 15. Supplementery Notes Thir research was conducted under Tasks No. AM-A-73-FSY-27 and AM-D-74-PSY-27. 16. Abstreet Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly wore vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Stetement 19. Security Classif. (of this report) 20: Security Classif. (of this pege) 10. Net static 11. Net of Pages 11. Net of Pages <td>12. Sponsoring Agency Name and Addres=</td> <td></td> <td></td> <td></td> <td></td>	12. Sponsoring Agency Name and Addres=					
Federal Aviation Administration 14. Spensoring Agency Code 800 Independence Avenue, S. W. 14. Spensoring Agency Code 15. Supplementary Notes 14. Spensoring Agency Code 16. Abstract Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other statid differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo cular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Statement 18. Distribution Statement Availability is unlimited. Document may be released to the National Technical Information Serv	Office of Aviation Medicin	e		OAM Report		
800 Independence Avenue, S. W. 14. Spensoring Agency Code Washington, D. C. 20591 15. Supplementary Notes This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstreet Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour nod +chour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more vestibular nystagmus than bot the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Statement 19. Security Classif. (of this report) 20: Security Classif. (of this pege) 21. No. o	Federal Aviation Administr	ation				
Washington, D. C. 2001 15. Supplementary Mets This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Aburget Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more tracking errors and had significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Statement Drugs Angular Acceleration Pricestil (of this report) 20: Securi	800 Independence Avenue, S	. W.	14.	Sponsoring Agency (ode	
This research was conducted under Tasks No. AM-A-73-PSY-27 and AM-D-74-PSY-27. 16. Abstract Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more tracking errors and had significantly more vestibular mystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Stotement Drugs Angular Acceleration Performance Vestibular Nystagmus 20: Security Clessit. (of this pege) <td< td=""><td>Washington, D. C. 20391</td><td></td><td></td><td></td><td></td></td<>	Washington, D. C. 20391					
16. Abstract Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more tracking errors and had significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance degradation during angular motion. The primary cause of this performance in static environments were the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Statement 19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price 19. Security Classified 10. Unclassified 8 \$3.00 \$3.00	This research was conducte	d under Tasks	No. AM-A-73-PSY-2	7 and AM-D-74	4-PSY-27.	
Thirty young men were randomly assigned in equal numbers to one of the following groups: placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more tracking errors and had significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance degradation during angular motion. The primary cause of this performance degradation during angular motion. The primary cause of this performance degradation during angular motion. The primary cause of this performance degradation during angular motion. The primary cause of this performance degradation during angular motion. The primary cause of this performance degradation during angular motion. The primary cause of this performance functional fixation is impaired. 17. Key Words 18. Distribution Statement 19. Security Classified 20: Security Classif, (of this page) <td>16 Abstract</td> <td></td> <td></td> <td></td> <td></td>	16 Abstract					
groups:placebo (lactose), secobarbital (100 mg), or d-amphetamine (10 mg). The drugs or placebo were administered in capsules in a double-blind procedure follow- ing practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made 	Thirty young men were rand	omly assigned	in equal numbers	to one of the	e following	
drugs or placebo were administered in capsules in a double-blind procedure following practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions.Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more tracking errors and had significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions.These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired.17. Key Words18. Distribution Storement Availability is unlimited. Document may be released to the National Technical Information Service, Springfield, Virginia 22151, for sale to the public.19. Security Classif. (of this report)20: Security Classif. (of this pege)21. No. of Pages22. Price 819. Security Classified00: Security Classified8\$3.00	groups: placebo (lactose)	, secobarbita	1 (100 mg), or d-a	mphetamine (10 mg). The	
ing practice at a tracking task and baseline determinations of tracking performance levels in both static (stationary) and dynamic (angular acceleration) conditions. Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more tracking errors and had significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired.17. Key Words Drugs Angular Acceleration Performance Nystagmus18. Distribution Stotement Availability is unlimited. Document may be released to the National Technical Informa- tion Service, Springfield, Virginia 22151, for sale to the public.19. Security Classified20: Security Classified21. No. of Pages \$3.00	drugs or placebo were admi	nistered in c	apsules in a doubl	e-blind proc	edure follow-	
levels in both static (stationary) and dynamic (angular acceleration) conditions.Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests wereconducted inside a Stille-Werner rotator and were in total darkness with theexception of the illuminated tracking display. With the rotator stationary,d-amphetamine subjects performed significantly better than controls during the2-hour and 4-hour post-drug sessions; no other static differences among the groupswere significant. However, during angular acceleration, secobarbital subjects madesignificantly more tracking errors and had significantly more vestibular nystagmusthan both the control and the d-amphetamine groups for all post-drug sessions.These findings agree with our previous studies of alcohol effects: depressantdrugs may have little or no deleterious influence on tracking performance instatic environments, but may produce marked performance degradation during angularmotion. The primary cause of this performance impairment appears to be a vestibuloocular one; the ability to inhibit vestibular nystagmus by visual fixation isimpaired.17. Key WordsNystagmus18. Distribution StatementNystagmus19. Security Classif. (of this report)20: Security Classif. (of this report)20: Security Classif. (of this page)21. No. of Pages22. PriceUnclassified8\$3.00	ing practice at a tracking	task and bas	eline determinatio	ns of tracki	ng performance	
Tests were scheduled 1, 2, and 4 hours after capsule ingestion; all tests were conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more tracking errors and had significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired.17. Key Words Drugs Nystagmus18. Distribution Statement Availability is unlimited. Document may be released to the National Technical Informa- tion Service, Springfield, Virginia 22151, for sale to the public.19. Security Classif. (of this report) Unclassified20: Security Classif. (of this pege)21. No. of Pages 22. Price 822. Price	levels in both static (sta	tionary) and	dynamic (angular a	cceleration)	conditions.	
conducted inside a Stille-Werner rotator and were in total darkness with the exception of the illuminated tracking display. With the rotator stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more tracking errors and had significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo- ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired.17. Key Words Drugs Nystagmus18. Distribution Statement Availability is unlimited. Document may be released to the National Technical Informa- tion Service, Springfield, Virginia 22151, for sale to the public.19. Security Clessif. (of this report) Unclassified20: Security Clessif. (of this page)21. No. of Pages 822. Price 8	Tests were scheduled 1, 2,	and 4 hours	after capsule inge	stion; all t	ests were	
exception of the filuminated tracking display. With the foldor stationary, d-amphetamine subjects performed significantly better than controls during the 2-hour and 4-hour post-drug sessions; no other static differences among the groups were significant. However, during angular acceleration, secobarbital subjects made significantly more tracking errors and had significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo- ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired.17. Key Words Drugs Nystagmus18. Distribution Statement Availability is unlimited. Document may be released to the National Technical Informa- tion Service, Springfield, Virginia 22151, for sale to the public.19. Security Classified20: Security Classif. (of this page)21. No. of Pages 22. Price 8 \$3.00	conducted inside a Stille-	Werner rotato	or and were in tota	I darkness w	ith the	
1-amplietamine subjects performed significantly better than controls during end2-hour and 4-hour post-drug sessions; no other static differences among the groupswere significant. However, during angular acceleration, secobarbital subjects madesignificantly more tracking errors and had significantly more vestibular nystagmusthan both the control and the d-amphetamine groups for all post-drug sessions.These findings agree with our previous studies of alcohol effects: depressantdrugs may have little or no deleterious influence on tracking performance instatic environments, but may produce marked performance degradation during angularmotion. The primary cause of this performance impairment appears to be a vestibulo-ocular one; the ability to inhibit vestibular nystagmus by visual fixation isimpaired.17. Key WordsDrugsAngular AccelerationNystagmus18. Distribution StatementNystagmus19. Security Classif. (of this report)20: Security Classif. (of this report)20: Security Classif. (of this page)21. No. of Pages22. PriceUnclassified8\$3.00	d amphotomino subjects per	formed signif	icantly better the	n controle d	uring the	
17. Key Words 18. Distribution Statement 17. Key Words 18. Distribution Statement 17. Key Words 18. Distribution Statement 17. Key Words 20: Security Classif. (of this report) 19. Security Classif. (of this report) 20: Security Classif. (of this page) 19. Security Classif. (of this report) 20: Security Classif. (of this page) 19. Security Classif. (of this report) 20: Security Classif. (of this page) 19. Security Classif. (of this report) 20: Security Classif. (of this page) 19. Security Classif. (of this report) 20: Security Classif. (of this page) 19. Security Classif. (of this report) 20: Security Classif. (of this page) 19. Security Classif. (of this report) 20: Security Classif. (of this page) 19. Security Classif. (of this report) 20: Security Classif. (of this page) 19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price	2-hour and (-hour post-dr	a consioner r	o other static dif	ferences amo	ng the groups	
Were significantly more tracking errors and had significantly more vestibular nystagmus than both the control and the d-amphetamine groups for all post-drug sessions. These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired.17. Key Words Drugs Performance Nystagmus18. Distribution Stotement Availability is unlimited. Document may be released to the National Technical Informa- tion Service, Springfield, Virginia 22151, for sale to the public.19. Security Classified20: Security Classified21. No. of Pages 822. Price	were significant However	during angu	lar acceleration	secobarbital	subjects made	
The security ClassifiedThe security ClassifiedThe security ClassifiedThe security Classified10. Security Classified10. Security Classified10. Security Classified20. Security Classified20. Security Classified21. No. of Pages21. PriceNo. of Pages21. No. of Pages21. PriceNo. of Pages21. Price	significantly more tracking	g errors and	had significantly	more vestibu	lar nystagmus	
These findings agree with our previous studies of alcohol effects: depressant drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Statement Drugs Angular Acceleration Performance Vestibular Vestibular Nystagmus 18. Distribution Statement Availability is unlimited. Document may be released to the National Technical Information Service, Springfield, Virginia 22151, for sale to the public. 19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price Unclassified 8 \$3.00	than both the control and	the d-ampheta	mine groups for al	1 post-drug	sessions.	
drugs may have little or no deleterious influence on tracking performance in static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo-ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Statement Drugs Angular Acceleration Performance Nystagmus 18. Distribution Statement 19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price Nuclassified 8	These findings agree with	our previous	studies of alcohol	effects: d	epressant	
static environments, but may produce marked performance degradation during angular motion. The primary cause of this performance impairment appears to be a vestibulo-ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Statement Drugs Angular Acceleration Performance Nystagmus 18. Distribution Statement Availability is unlimited. Document may be released to the National Technical Information Service, Springfield, Virginia 22151, for sale to the public. 19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price Unclassified 8 \$3.00	drugs may have little or r	o deleterious	influence on trac	king perform	ance in	
motion. The primary cause of this performance impairment appears to be a vestibulo- ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words 18. Distribution Statement Drugs Angular Acceleration Performance 18. Distribution Statement Nystagmus Vestibular Availability is unlimited. Document may be released to the National Technical Informa- tion Service, Springfield, Virginia 22151, for sale to the public. 19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price Unclassified 8 \$3.00	static environments, but may produce marked performance degradation during angular					
ocular one; the ability to inhibit vestibular nystagmus by visual fixation is impaired. 17. Key Words Drugs Angular Acceleration Performance Vestibular Nystagmus Vestibular 19. Security Classif. (of this report) 20: Security Classif. (of this page) Unclassified 21: No. of Pages 21: No. of Pages 22. Price 8 \$3.00	motion. The primary cause	of this perf	formance impairment	appears to	be a vestibulo-	
impaired.17. Key Words18. Distribution StatementDrugsAngular Acceleration PerformanceNystagmus18. Distribution StatementAvailability is unlimited. Document may be released to the National Technical Informa- tion Service, Springfield, Virginia 22151, for sale to the public.19. Security Classif. (of this report)20: Security Classif. (of this page)21. No. of Pages22. Price 8Unclassified8	ocular one; the ability to	inhibit vest	ibular nystagmus b	y visual fix	ation is	
17. Key Words 18. Distribution Statement Drugs Angular Acceleration Performance Vestibular Nystagmus Vestibular 19. Security Classif. (of this report) 20: Security Classif. (of this page) Unclassified 21. No. of Pages 21. No. of Pages 22. Price 8 \$3.00	impaired.	impaired.				
17. Key Words 18. Distribution Statement Drugs Angular Acceleration Performance Vestibular Nystagmus Vestibular 19. Security Classif. (of this report) 20: Security Classif. (of this page) Unclassified 21. No. of Pages 22. Price 8 \$3.00						
17. Key Words 18. Distribution Statement Drugs Angular Acceleration Performance Vestibular Nystagmus Vestibular 19. Security Classif. (of this report) 20: Security Classif. (of this page) Unclassified 21. No. of Pages 22. Price 8 \$3.00						
Drugs Angular Acceleration Performance Vestibular Nystagmus Vestibular 19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price Unclassified 8	17 K. W. J.		19 District of a first			
Drugs Angular Acceleration Availability is unlimited. Document may be released to the National Technical Information Service, Springfield, Virginia 22151, for sale to the public. 19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price Unclassified Unclassified 8 \$3.00	Draw words	A	Availability in Statement	limited D	cument men he	
NystagmusLorensee to the national rechnical informationNystagmustion Service, Springfield, Virginia 22151, for sale to the public.19. Security Classif. (of this report)20: Security Classif. (of this page)21. No. of Pages22. PriceUnclassifiedUnclassified8\$3.00	Berfermanen Vestilieren Vestil		released to the N	ational Tech	ical Informa-	
19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price Unclassified Unclassified 8 \$3.00	Nuctormance Vestibular Ition Service		tion Service. Spr	ingfield. Vir	ginia 22151.	
19. Security Classif. (of this report) 20: Security Classif. (of this page) 21. No. of Pages 22. Price Unclassified Unclassified 8 \$3.00	Mystaguus		for sale to the p	ublic.		
19. Security Classif. (of this report)20: Security Classif. (of this page)21. No. of Pages22. PriceUnclassifiedUnclassified8\$3.00						
Unclassified Unclassified 8 \$3.00	19. Security Classif. (of this report)	20: Security Clas	sif. (of this page)	21. No. of Pages	22. Price	
	Unclassified	Unclassified		8	\$3.00	

Form DOT F 1700.7 (8-69)

EFFECTS OF SECOBARBITAL AND D-AMPHETAMINE ON TRACKING PERFORMANCE DURING ANGULAR ACCELERATION

I. Introduction.

Most studies of the effects of drugs on performance have been conducted under stationary conditions. In an aviation environment, however, an important aspect of drugs concerns their effects on performance during motion. Recent joint studies by CAMI and USNAMRL^{3 6 12} have shown that the deleterious effects of alcohol on psychomotor performance in the laboratory are more pronounced during angular motion than under stationary conditions. This difference may be attributed to the interfering effects of alcohol on the ability of the subject to reduce with visual cues the nystagmic eye movements which occur as a result of angular stimulation of the vestibular system. Since alcohol acts primarily as a central nervous system depressant, it seems likely that other drugs which have depressive effects may similarly affect an individual's visual fixation ability and, consequently, his psychomotor performance during vestibular stimulation. Moreover, there is no information presently available concerning the effects of an analeptic, as opposed to a depressant, on eye-hand coordination during concomitant vestibular stimulation. Consequently, the purpose of this study was to extend our knowledge of the interaction of tracking performance, angular acceleration, and drugs to include the effects of both a commonly used depressant other than alcohol (secobarbital) and a commonly used analeptic (d-amphetamine).

II. Method.

Subjects. Thirty male college students ranging in age from 20 to 30 years served as subjects. Before any testing, 10 subjects each were randomly assigned by a double-blind procedure to one of three groups: a placebo, secobarital, or d-amphetamine group. None had any previous laboratory experience involving vestibular stimulation. Subjects were not allowed to smoke or drink beverages containing caffine, except during the 2-hour lunch period which preceded the final test session.

Apparatus. The angular stimulation was provided by a modified Stille-Werner rotation device. The subject was seated in an upright position directly over the center of rotation, with his head fixed in a headrest so that the lateral semicircular canals were approximately in the plane of rotation. The device was programmed, using a Wavetek signal generator, to provide a triangular waveform stimulus of 10°/sec² with a period of 48 seconds and a peak velocity of 120°/sec in both clockwise and counterclockwise directions.

A one-degree-of-freedom compensatory tracking task consisting of an aircraft localizer/glideslope indicator (attached to the front of the rotation device and a joy stick (mounted directly in front of the subject) was used as a measure of psychomotor (eye-hand) coordination. The vertical needle on the instrument was deflected to the left and right of center by a sinusoidal forcing function with a 14-second period. The needle movement was thus in the same approximate plane as the eye movements arising from the vestibular stimulation. The subject's task was one of keeping the needle in the center or null position by compensatory movements of the joy stick. Deviations from the null position were considered as errors and a voltage proportional to these deviations was electronically integrated over 1-second intervals and recorded. Further details concerning the operation of the tracking task are presented elsewhere.5

Light was projected through a tube to illuminate the display. A card, coated with the same white paint as the needle, was placed in front of the instrument for luminance calibrations.

We gratefully acknowledge assistance in data collection and scoring by Carolyn Eubanks, Martha Manley, and Cynthia Mitchell.

The study was supported in part by NIH Grant Numher T01 NR 05418-09 from NINDS.

The luminance was checked with a MacBeth illuminometer and set at one ft.L. The test room was otherwise in total darkness.

Electrodes were taped beside the outer canthus of each eye to record horizontal eye movements. Calibration of the horizontal eye movements was accomplished by having the subject sweep his eyes between two small flashing lights on the front of the rotator; the lights subtended a visual angle of 15°. Eye movements and tracking errors were recorded on a Beckman Type T electroencephalograph.

Procedure. Following instructions, each subject was given two minutes of static tracking practice, i.e., with the rotator stationary. This was followed by a practice session comprising one minute of static tracking, 2.5 minutes of dynamic tracking (during five complete cycles of rotation), and three minutes of rotation in the dark (the latter was conducted for purposes other than those of the presently reported experiment). A predrug session and three post-drug sessions were identical to the practice session.

Following the pre-drug session, the subjects consumed their respective capsules on an empty stomach: either 10 mg of d-amphetamine, 100 mg of secobarbital, or a placebo containing lactose. The drugs were administered using a double-blind procedure. Post-drug sessions were conducted 1, 2, and 4 hours after administration of the drugs with blood pressure and heart rate monitored immediately prior to each of the test sessions.

Scoring. One-second intervals of tracking error were measured, summed, and averages obtained for both the static and dynamic conditions. The amount of slow-phase eye displacement was measured and the number of nystagmic eye movements was counted across the last two cycles of rotation during dynamic tracking. Mean values in degrees per second and beats per second were calculated and used as measures of nystagmic output. Scoring was accomplished without knowledge of the group (drugs or placebo) to which any subject belonged, and these absolute values were used in the statistical analyses.

Table 1

Mean pulse rates and blood pressure measures (systolic/diastolic)

obtained during each pre- and post-drug session for subjects in

the secobarbital, d-amphetamine, and placebo groups.

		Post	Post-Drug Sessions		
Group	Pre-Drug	<u>1-hr.</u>	<u>2-hr.</u>	<u>4-hr.</u>	
		Pulse	Rate		
secobarbital	65.1	65.2	65.5	70.0	
d-amphetamine	66.7	66.0	70.9	78.2	
placebo	72.2	65.8	67.2	72.6	
		Blood P	ressure		
secobarbital	115/73	114/73	112/73	117/72	
d-amphetamine	116/73	122/75	126/76	111/73	
placebo	116/77	120/79	117/79	121/77	

Table 2

Levels of statistical significance (Not Significant; $\underline{p} < .05$; $\underline{p} < .01$; $\underline{p} < .001$) obtained within groups by \underline{t} tests. Comparisons were made between tracking scores and measures of nystagmus from the predrug session and each post-drug session for the secobarbital d-amphetamine, and placebo groups separately.

		Pre-Drug Session vs.		
Measure	Group	1-hr.	<u>2-hr.</u>	4-hr.
Static	secobarbital	N.S.	N.S.	N.S.
Error	d-amphetamine	N.S.	.05*	.01*
	placebo	N.S.	N.S.	N.S.
Dynamic	secobarbital	.01**	.001**	N.S.
Error	d-amphetamine	N.S.	.001*	.05*
	placebo	N.S.	N.S.	.01*
Slow-Phase Nystagmus	secobarbital	.01**	.01**	.01**
	d-amphetamine	N.S.	.01*	.001*
	placebo	. 05*	N.S.	N.S.
Nystagmic Beats	secobarbital	.001**	.001**	.01**
	d-amphetamine	N.S.	.05*	N.S.
	placebo	N.S.	N.S.	N.S.

* indicates significantly less of the measure ** indicates significantly more of the measure

For graphic presentation, however, "change" scores were computed. For each group and each measure, the mean score for the pre-drug session was plotted as a zero base and the percentage of increase or decrease in subsequent scores for a given measure (i.e., in sessions which followed administration of a drug or placebo) was plotted as "per cent increase" or "per cent decrease" from the pre-drug level.



FIGURE 1. Changes in tracking performance under static (stationary) and dynamic (angular acceleration) conditions. Error scores for the pre-trial (before ingestion of the drug or placebo capsule) were set at O. Error scores for the post-ingestion sessions were converted to percentages of increase or decrease from the pre-ingestion baseline.

III. Results.

Cardiovascular Measures

Means and standard deviations for heart rate and blood pressure are presented in Table 1. A rise in both measures occurred for the d-amphetamine group after administration of the drug, but these changes were not statistically significant at the .05 level. Moreover, none of the measures of heart rate or blood pressure for either the secobarbital or control group changed significantly (p>.05) across sessions. (Goldstein, Searle, and Schimke^r also failed to find any effect of 10 mg of d-amphetamine or of 200 mg of secobarital on blood pressure and heart rate, although Collins and Poe⁴ reported statistically reliable increases in these measures following 12 mg doses of amphetamine administered subcutaneously.) Thus, the presence or absence of the drugs could not be ascertained by these cardiovascular measures.

Static Tracking

Within-Group Comparisons of Tracking Performance. Subjects in the placebo and the secobarbital groups evidenced little change in static tracking error from the pre-drug through the Levels of statistical significance (Not Significant; p < .05; p < .01) obtained between groups with analyses of covariance of tracking and nystagmus scores. Duncan's New Multiple Range Test was then used to determine which of the secobarbital (S), d-amphetamine (D), and placebo (P) groups differed (<; >) in scores during the sessions following drug administration.

Measure	<u>1-hr.</u>	<u>2-hr.</u>	<u>4-hr.</u>
Static Tracking	N.S.	.05	.05
Error		D < P	D < P
Dynamic Tracking	.01	.01	.01
Error	S > D	S > D	S > D
	S > P	S > P	S > P
Slow-Phase	.01	.01	.01
Nystagmus	S > D	S > D	S > D
	S > P	S > P	S > P
Nystagmic	.01	.01	.01
Dears	S > D	S > D	S > D
	S > P	S > P	S > P

Post-Drug Sessions

post-drug sessions (Figure 1); all of the postdrug static tracking error means were within $\pm 11\%$ of their respective pre-drug levels and none of these differences was statistically significant at the .05 level by t test (Table 2). In contrast, subjects in the d-amphetamine group evidenced a steady decrease in tracking error from the pre-drug session through the 4-hour post-drug tests. Some improvement with practice in static tracking performance at this task is not an unusual finding even for non-drugged subjects.³ ^e However, while most of the improvement in tracking performance for the d-amphetamine group occurred during the session conducted 1

5

hour after drug administration (18%), only the 2-hour and the 4-hour post-drug scores were statistically lower than the pre-drug level (p < .05 and .01, respectively).

Between-Group Comparisons of Tracking Performance. Comparisons of static tracking performance among the three groups were made using analysis of covariance and Duncan's New Multiple Range Test; results are presented in Table 3. During static tracking, the only statistically significant differences (p < .05 in both cases) occurred between the placebo and d-amphetamine groups for the 2-hour and 4-hour post-drug sessions; the d-amphetamine group performed with less error during these sessions. Thus, d-amphetamine had some positive effect on static tracking performance; a stronger conclusion does not seem warranted since (a) the placebo group in this study showed little performance improvement while in two previous studies3 6 control groups decreased tracking errors by approximately 15% over similar time and test periods, and (b) there were no significant differences in performance between the group receiving d-amphetamine and the secobarbital group.

Dynamic Tracking

Within-Group Comparisons of Tracking Performance. Both the d-amphetamine and control groups exhibited steady improvement in dynamic tracking performance across sessions. This predrug to post-drug improvement for the two groups (which must be considered largely as a practice effect^{3 6 12}) ranged from 3% to 28% across sessions (see Figure 1) and was statistically significant by t tests two hours and four hours after administration of the capsules (p < .001 and.05, respectively) for the d-amphetamine group, and four hours post-administration (p < .01) for the placebo group (Table 2). Although there was an initial tendency for the subjects receiving the d-amphetamine to show slightly greater performance improvement than the control subjects, none of the differences between the two groups was statistically significant. On the other hand, subjects in the secobarbital group evidenced a dramatic increase in tracking error (66%) one hour after receiving the drug; during subsequent sessions their tracking error was reduced, but the error scores four hours after administration of the drug were still 11% above the pre-drug levels. This pre-drug to post-drug deterioration in tracking performance for the secobarital group was statistically significant for the 1- and 2-hour post-drug sessions (p < .01 and .001, respectively).

Between-Group Comparisons of Tracking Performance. Results of an analysis of covariance and Duncan's New Multiple Range Test indicated that the dynamic tracking performance of subjects in the secobarbital group was significantly poorer than that of subjects in both the placebo and d-amphetamine groups for all of the post-drug sessions (p < .01 in each case). Although the d-amphetamine group had less tracking error than placebo subjects during the 1-hour and 2-hour post-drug sessions (and particularly during the latter when a maximal effect of the drug might be expected; see Figure 2), none of these differences was statistically significant.

Nystagmus During Tracking

Within-Group Comparisons of Nystagmic Output. With regard to both the slow-phase velocity and the number of nystagmic eye movements, subjects in the placebo and d-amphetamine groups exhibited a steady decline from the pre-drug through the post-drug sessions (Figure 2); several of these differences were statistically significant (Table 2). In contrast, for subjects in the secobarbital group, both slow-phase nystagmus and number of nystagmic beats increased significantly during the 1-hour post-drug session (p < .01 and .001, respectively) and, although there was a gradual return toward the pre-drug level, both measures of nystagmus for this group remained significantly above the pre-drug levels through the 4-hour post-drug session (p < .01).

Between-Group Comparisons of Nystagmic Output. The slow-phase velocity measures and the number of nystagmic beats recorded for subjects in each group were submitted to analyses of covariance and Duncan's New Multiple Range Test. Scores for both measures were significantly higher (p < .01 in every case) for secobarbital subjects than scores for the placebo and d-amphetamine groups during each of the post-drug testing sessions (Table 3). Only one appreciable difference occurred between the placebo and d-amphetamine groups (at the 2-hour post-drug sessions; see Figure 2) but that difference was not statistically reliable.



FIGURE 2. Slow-phase displacement of nystagmus and the number of nystagmic beats obtained while subjects were tracking in the dynamic condition. Measures for the pre-trial (before ingestion of the drug or placebo capsule) were set at 0. Measures for the post-ingestion sessions were converted to percentages of increase or decrease from the pre-ingestion baseline.

Conclusion

The obtained decrement in tracking performance for the secobarbital subjects during angular stimulation is correlated with a considerable increase in the number and velocity of nystagmic eye movements with attendant visual blurring. Thus, these deleterious effects of secobarbital appear to be similar to those produced by alcohol; both apparently interfere with the ability of the visual system to suppress nystagmic eye movements which result from angular stimulation of the vestibular system. Further support of such an effect of barbiturates appears in an earlier study of optokinetic and caloric nystagmus by Rashbass and Russell¹⁰ where the authors found that the barbiturate sodium amytal "... abolished the inhibiting effect of visual fixation" (p. 355). Barbiturates apparently suppress optokinetic nystagmus¹² and interfere with smooth tracking movement⁹¹⁰ and visual fixation ability¹⁰ in much the same fashion as does alcohol.3 6 11 12

The present data support our previous findings^{3 6 12} with alcohol, i.e., the effect of at least

some depressant drugs on performance may not be evident in a stationary environment, but may be substantial during angular stimulation of the vestibular system. Such degradation in performance appears primarily attributable to impaired visual acuity resulting from the inability to suppress vestibular nystagmus by visual means.5 8 In addition to nystagmus, however, motion may contribute to performance declines by producing other effects, such as distraction, which essentially make the tracking task more complex and more susceptible to the influence of depressant drugs. d-Amphetamine, an alerting drug, appeared not to affect dynamic tracking although it had some facilitory effect on static tracking. In any event, future evaluations of effects of drugs on performance should take into account the influence of motion. Any drug which interferes with the ability of a pilot to fixate and read cockpit instruments during flight would severely compromise his ability to react properly during maneuvers, especially under IFR conditions.

REFERENCES

- Bender, M. B., and F. H. O'Brien: The Influence of Barbiturate on Various Forms of Nystagmus, AMER-ICAN JOURNAL OF OPTHALMOLOGY, 29:1541-1552, 1946.
- Bergman, P. S., M. Nathanson, and M. B. Bender: Electrical Recordings of Normal and Abnormal Eye Movements Modified by Drugs, ARCHIVES OF NEUROLOGY AND PSYCHIATRY, 67:357-374, 1952.
- Collins, W. E., R. D. Gilson, D. J. Schroeder, and F. E. Guedry: Effects of Alcohol Ingestion on Tracking Performance During Angular Acceleration, JOURNAL OF APPLIED PSYCHOLOGY, 55:559-563, 1971.
- Collins, W. E., and R. H. Poe: Amphetamine, Arousal, and Human Vestibular Nystagmus, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERA-PEUTICS, 138:120–125, 1962.
- Gilson, R. D., F. E. Guedry, and A. J. Benson: Influence of Vestibular Stimulation and Display Luminance on the Performance of a Compensatory Tracking Task, AEROSPACE MEDICINE, 41:1231– 1237, 1970.
- Gilson, R. D., D. J. Schroeder, W. E. Collins, and F. E. Guedry: Effects of Different Alcohol Dosages and Display Illumination on Tracking Performance During Vestibular Stimulation, AEROSPACE MEDI-CINE, 43:656-660, 1972.

- Goldstein, A., B. W. Searle, and R. T. Schimke: Effects of Secobarbital and d-Amphetamine on Psychomotor Performance of Normal Subjects, JOUR-NAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 180:55–58, 1960.
- Guedry, F. E.: Relations Between Vestibular Nystagmus and Visual Performance, AEROSPACE MED-ICINE, 39:570-579, 1968.
- Norris, H.: The Time Course of Barbiturate Action in Man Investigated by Measurement of Smooth Tracking Eye Movement, BRITISH JOURNAL OF CHEMOTHERAPY, 33:117-128, 1968.
- Rashbass, C., and G. F. M. Russell: Action of a Barbiturate Drug (Anylobarbitone Sodium) on the Vestibulo-Ocular Reflex, BRAIN, 84:329-335, 1961.
- Schroeder, D. J.: Some Effects of Alcohol on Nystagmus and Vertigo During Caloric and Optokinetic Stimulation, ANNALS OF OTOLOGY, RHINOLOGY, AND LARYNGOLOGY, 81:218-229, 1972.
- Schroeder, D. J., R. D. Gilson, F. E. Guedry, and W. E. Collins: Effects of Alcohol on Nystagmus and Tracking Performance During Laboratory Angular Accelerations About the Y and Z Axes, AEROSPACE MEDICINE, 44:477-483, 1973.